Breaking Finance News

A statement released earlier today by Zacks Investment Research about Alder Biopharmaceuticals Inc (NASDAQ:ALDR) raises the target price to $27.00

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) had its target price raised to $27.00 by Zacks Investment Research in a report released 11/29/2016. The new target price indicates a possible upside of 0.14% based on the company's last stock close price.

Yesterday Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded 2.54% higher at $23.65. The company’s 50-day moving average is $27.81 and its 200-day moving average is $29.09. The last stock close price is down -16.64% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 899,414 shares of the stock were exchanged, up from an average trading volume of 612,686

See Chart Below

Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder Biopharmaceuticals Inc has a 52 week low of $15.82 and a 52 week high of $38.69 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 4 firms have issued a report on the stock. The consensus target price is $47.00 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.